N(omega)-nitro-L-arginine methyl ester protects retinal neurons against N-methyl-D-aspartate-induced neurotoxicity in vivo. 1997

C Morizane, and K Adachi, and I Furutani, and Y Fujita, and A Akaike, and S Kashii, and Y Honda
Department of Pharmacology, Faculty of Pharmaceutical Sciences, Kyoto University, Japan.

We investigated whether the inhibition of nitric oxide (NO) synthesis with N(omega)-nitro-L-arginine methyl ester (L-NAME), a competitive inhibitor of NO synthase, affects N-methyl-D-aspartate (NMDA)-induced neurotoxicity in the rat retina in vivo. A single intravitreal injection of NMDA damaged the ganglion cell layer and the inner plexiform layer without affecting the other retinal layers 7 days after injection. Intravitreal injection of (5R,10S)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclo-hepten-5, 10-imine hydrogen maleate (MK-801) with NMDA significantly reduced NMDA-induced degeneration of the retina. NMDA-induced degeneration was also prevented by intravitreal injection of L-NAME but not of D-NAME. The protective effect of L-NAME was antagonized by L-arginine. These results suggest that NO plays an important role in NMDA-induced excitotoxic degeneration in the retina.

UI MeSH Term Description Entries
D008297 Male Males
D009474 Neurons The basic cellular units of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the NERVOUS SYSTEM. Nerve Cells,Cell, Nerve,Cells, Nerve,Nerve Cell,Neuron
D012160 Retina The ten-layered nervous tissue membrane of the eye. It is continuous with the OPTIC NERVE and receives images of external objects and transmits visual impulses to the brain. Its outer surface is in contact with the CHOROID and the inner surface with the VITREOUS BODY. The outer-most layer is pigmented, whereas the inner nine layers are transparent. Ora Serrata
D002452 Cell Count The number of CELLS of a specific kind, usually measured per unit volume or area of sample. Cell Density,Cell Number,Cell Counts,Cell Densities,Cell Numbers,Count, Cell,Counts, Cell,Densities, Cell,Density, Cell,Number, Cell,Numbers, Cell
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001120 Arginine An essential amino acid that is physiologically active in the L-form. Arginine Hydrochloride,Arginine, L-Isomer,DL-Arginine Acetate, Monohydrate,L-Arginine,Arginine, L Isomer,DL Arginine Acetate, Monohydrate,Hydrochloride, Arginine,L Arginine,L-Isomer Arginine,Monohydrate DL-Arginine Acetate
D013237 Stereoisomerism The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Molecular Stereochemistry,Stereoisomers,Stereochemistry, Molecular,Stereoisomer
D014822 Vitreous Body The transparent, semigelatinous substance that fills the cavity behind the CRYSTALLINE LENS of the EYE and in front of the RETINA. It is contained in a thin hyaloid membrane and forms about four fifths of the optic globe. Vitreous Humor,Bodies, Vitreous,Body, Vitreous,Humor, Vitreous,Humors, Vitreous,Vitreous Bodies,Vitreous Humors

Related Publications

C Morizane, and K Adachi, and I Furutani, and Y Fujita, and A Akaike, and S Kashii, and Y Honda
December 1995, European journal of pharmacology,
C Morizane, and K Adachi, and I Furutani, and Y Fujita, and A Akaike, and S Kashii, and Y Honda
April 1996, American journal of therapeutics,
C Morizane, and K Adachi, and I Furutani, and Y Fujita, and A Akaike, and S Kashii, and Y Honda
October 2011, Journal of neuroscience research,
C Morizane, and K Adachi, and I Furutani, and Y Fujita, and A Akaike, and S Kashii, and Y Honda
January 1998, Journal of leukocyte biology,
C Morizane, and K Adachi, and I Furutani, and Y Fujita, and A Akaike, and S Kashii, and Y Honda
August 2002, Neuroscience letters,
C Morizane, and K Adachi, and I Furutani, and Y Fujita, and A Akaike, and S Kashii, and Y Honda
March 1994, European journal of pharmacology,
C Morizane, and K Adachi, and I Furutani, and Y Fujita, and A Akaike, and S Kashii, and Y Honda
September 1999, The European journal of neuroscience,
C Morizane, and K Adachi, and I Furutani, and Y Fujita, and A Akaike, and S Kashii, and Y Honda
January 2002, Kidney & blood pressure research,
C Morizane, and K Adachi, and I Furutani, and Y Fujita, and A Akaike, and S Kashii, and Y Honda
July 2004, Biochemical pharmacology,
C Morizane, and K Adachi, and I Furutani, and Y Fujita, and A Akaike, and S Kashii, and Y Honda
August 2004, Shock (Augusta, Ga.),
Copied contents to your clipboard!